Open access
Open access
Powered by Google Translator Translator

Oncology – Gynecologic

RCT: Lenvatinib plus pembrolizumab improve outcomes compared to chemotherapy in patients with advanced endometrial cancer.

21 Jan, 2022 | 09:46h | UTC

Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer – New England Journal of Medicine

 

Commentary on Twitter

 


O-RADS MRI Risk Stratification System: Guide for Assessing Adnexal Lesions from the ACR O-RADS Committee.

20 Jan, 2022 | 08:59h | UTC

O-RADS MRI Risk Stratification System: Guide for Assessing Adnexal Lesions from the ACR O-RADS Committee – Radiology

 


RCT: Paclitaxel and Carboplatin noninferior to Paclitaxel and Ifosfamide in patients with carcinosarcoma of the uterus or ovary.

18 Jan, 2022 | 09:10h | UTC

Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)

Commentary: Paclitaxel Plus Carboplatin Is Reportedly Non-Interior to Paclitaxel and Ifosfamide in Uterine Carcinosarcoma – Cancer Network

 


Review: Endometrial cancer.

13 Dec, 2021 | 08:43h | UTC

Endometrial cancer – Nature Reviews Disease Primers (free for a limited period – if the link is paywalled, try this one)

Infographic: Endometrial cancer (free for a limited period – if the link is paywalled, try this one)

 


RCT: Cytoreductive surgery for relapsed ovarian cancer.

2 Dec, 2021 | 09:51h | UTC

Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer – New England Journal of Medicine

 


Recommendations for women with gynecological cancer who received non-standard care during the COVID-19 pandemic.

19 Nov, 2021 | 10:33h | UTC

British Gynaecological Cancer Society recommendations for women with gynecological cancer who received non-standard care during the COVID-19 pandemic – International Journal of Gynecological Cancer

 


A national HPV vaccination program in England was associated with an estimated reduction in cervical cancer rates of 87% for those offered the vaccine at age 12–13 years.

4 Nov, 2021 | 09:58h | UTC

The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study – The Lancet

Related:

Nationwide cohort study in Sweden shows HPV vaccination linked to reduced risk of invasive cervical cancer

CDC: 92% of Human Papillomavirus–Attributable Cancers can be Targeted by HPV Vaccination

Meta-Analysis: Population-level Impact of HPV Vaccination Programs

 

Commentary on Twitter

 


RCT: Pembrolizumab for persistent, recurrent, or metastatic cervical cancer.

26 Sep, 2021 | 21:43h | UTC

Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer – New England Journal of Medicine

Commentary: KEYNOTE-826: Pembrolizumab Plus Chemotherapy in Advanced Cervical Cancer – The ASCO Post

 


Guidelines for the peri-operative management of advanced ovarian cancer patients undergoing debulking surgery.

26 Aug, 2021 | 08:32h | UTC

European Society of Gynaecological Oncology guidelines for the peri-operative management of advanced ovarian cancer patients undergoing debulking surgery – International Journal of Gynecological Cancer

Editorial: Standardizing ovarian cancer surgery and peri-operative care: a European Society of Gynecological Oncology (ESGO) consensus statement

 


Cohort study: Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers.

20 Aug, 2021 | 08:39h | UTC

Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study – American Journal of Obstetrics and Gynecology

 

Commentary on Twitter

 


ASCO Resource-Stratified Guideline: Assessment of adult women with ovarian masses and treatment of epithelial ovarian cancer.

8 Aug, 2021 | 23:38h | UTC

Assessment of Adult Women With Ovarian Masses and Treatment of Epithelial Ovarian Cancer: ASCO Resource-Stratified Guideline – JCO Global Oncology

Commentary: ASCO Publishes Resource-Stratified Guideline on Assessment and Treatment of Ovarian Cancer – The ASCO Post

 


Review: Hyperthermic intraperitoneal chemotherapy for ovarian and colorectal cancer

7 May, 2021 | 08:23h | UTC

Hyperthermic Intraperitoneal Chemotherapy for Ovarian and Colorectal Cancer: A Review – JAMA Oncology (free for a limited period)

 


RCT: No benefit from immune checkpoint inhibitors in newly diagnosed stage III or IV ovarian cancer

25 Apr, 2021 | 20:57h | UTC

Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39) – Journal of Clinical Oncology

Editorial: Immune Checkpoint Inhibitors in Ovarian Cancer: Can We Bridge the Gap Between IMagynation and Reality?

 


RCT: Treatments for vulnerable older adult women with ovarian cancer compared

23 Apr, 2021 | 08:15h | UTC

Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer: A Randomized Clinical Trial – JAMA Oncology (free for a limited period)

Editorial: Vulnerable Older Adults With Ovarian Cancer—Time to Stop Undertreating (free for a limited period)

 


RCT: Secondary cytoreduction followed by chemotherapy vs. chemotherapy alone in platinum-sensitive relapsed ovarian cancer

10 Mar, 2021 | 08:18h | UTC

Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)

 

Commentary on Twitter

 


[Abstract Only] Nationwide cohort study in Sweden shows HPV vaccination linked to reduced risk of invasive cervical cancer

1 Oct, 2020 | 08:56h | UTC

HPV Vaccination and the Risk of Invasive Cervical Cancer – New England Journal of Medicine

News Release: HPV vaccine effective against cervical cancer – Karolinska Institutet

 


Stay Updated in Your Specialty

No spam, just news.